All In Biotech

NDA 022368 · Pharmaxis Europe

Aridol Kit

Mannitol · Inhalation

Last checked: Nov 20, 2026Latest source record: Aug 13, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Oct 5, 2010

Approved uses

1

Original approval plus efficacy supplements

Registered trials

387

88 Phase 3, 30 recruiting

FAERS reports

4,906

4,670 serious, 1,418 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF SEVERE BRONCHOSPASM Mannitol, the active ingredient in ARIDOL, acts as a bronchoconstrictor and may cause severe bronchospasm. Bronchial challenge testing with ARIDOL is for diagnostic purposes only. Bronchial challenge testing with ARIDOL should only be conducted by trained professionals under the supervision of a physician familiar with all aspects of the bronchial challenge test and the management of acute bronchospasm. Medications (such as short-acting inhaled beta-agonist) and equipment to treat severe bronchospasm must be present in the testing area. If severe bronchospasm occurs it should be treated immediately by administration of a short-acting inhaled beta-agonist. Because of the potential for severe bronchoconstriction, the bronchial challenge testing with ARIDOL should not be performed in any patient with clinically apparent asthma or very low baseline...

What it is approved for

From the label in effect Apr 23, 2026.

ARIDOL is indicated for the assessment of bronchial hyperresponsiveness in adult and pediatric patients 6 years of age or older who do not have clinically apparent asthma. Limitations of Use: ARIDOL is not a standalone test or a screening test for asthma. Bronchial challenge testing with ARIDOL should be used only as part of a physician's overall assessment of asthma. ARIDOL is a sugar alcohol indicated for the assessment of bronchial hyperresponsiveness in adult and pediatric patients 6 years of age or older who do not have clinically apparent asthma. ( 1 ) Limitations of Use: ARIDOL is not a standalone test or a screening test for asthma. Bronchial challenge testing with ARIDOL should be used only as part of a physician's overall assessment of asthma.

Mechanism: The precise mechanisms through which inhaled mannitol causes bronchoconstriction are not known.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • ARIDOL KIT · MANNITOL N/A,5MG,10MG,20MG,40MG · POWDER, INHALATION · Prescription
  • ARIDOL · MANNITOL 40MG · POWDER, INHALATION · Prescription
  • ARIDOL · MANNITOL 10MG · POWDER, INHALATION · Prescription
  • ARIDOL · MANNITOL 20MG · POWDER, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Mannitol" as an intervention, any sponsor and status, largest first.

All 387 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pain621
  • renal failure592
  • anxiety502
  • injury495
  • drug ineffective484
  • stress473
  • unevaluable event470
  • fear430
  • death415
  • renal impairment394
  • off label use393
  • emotional distress386

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004116
200579
200689
200759
200887
200973
2010105
2011578
2012255
2013106
2014144
2015123
2016223
2017242
2018215
2019187
2020220
2021304
2022376
2023394
2024395
2025316
2026219

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,010 on PubMed

Sponsor: Pharmaxis Europe · Also marketed as Aridol

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.